Lyka Labs

Which are the latest news on Lyka Labs?

Why is Lyka Labs Ltd falling/rising?

As of 05-Sep, Lyka Labs Ltd's stock price is rising to Rs 78.90, up 1.78%, driven by strong buying interest and consistent gains over the past six days. The stock is trading above key moving averages, indicating bullish sentiment and increased investor participation.

As of 05-Sep, Lyka Labs Ltd's stock price is rising, currently at Rs 78.90, reflecting an increase of Rs 1.38 or 1.78%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed the sector by 2.23% today and has been on a consecutive gain streak for the last six days, accumulating a total return of 8.07% during this period. Additionally, the stock reached an intraday high of Rs 79.07, indicating strong buying interest.<BR><BR>Moreover, Lyka Labs is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is often seen as a bullish signal. The rising investor participation is also noteworthy, with a delivery volume of 3.24k on September 3, which has surged by 267.62% compared to the 5-day average delivery volume. This increase in trading activity suggests that more investors are willing to hold the stock, further supporting its price rise. Overall, these factors contribute to the positive momentum in Lyka Labs Ltd's stock price.

Who are in the management team of Lyka Labs?

The management team of Lyka Labs includes Kunal Narendra Gandhi (Chairman, Managing Director, CEO), Yogesh B Shah (CFO), and several independent and non-executive directors, such as Sandeep P Parikh and Dhara P. Shah, who collectively guide the company's strategic direction.

The management team of Lyka Labs includes the following key members:<BR><BR>1. **Kunal Narendra Gandhi** - Chairman, Managing Director, and CEO<BR>2. **Sandeep P Parikh** - Non-Executive and Independent Director<BR>3. **Yogesh B Shah** - Executive Director and Chief Financial Officer<BR>4. **Dhara P. Shah** - Non-Executive and Independent Director<BR>5. **Kishore P Shah** - Company Secretary and Compliance Officer<BR>6. **Babulal Jain** - Independent Director<BR>7. **Prashant Godha** - Director<BR>8. **Shashil Mendonsa** - Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

What does Lyka Labs do?

Lyka Labs Ltd is a micro-cap pharmaceutical and biotechnology company, established in 1983, that manufactures various products including ayurvedic and animal health care items. As of June 2026, it reported net sales of 42 Cr and a net profit of 2 Cr.

Overview:<BR>Lyka Labs Ltd is a company engaged in the pharmaceuticals and biotechnology industry, operating within the micro cap market segment.<BR><BR>History:<BR>Lyka Labs Ltd was incorporated in 1983, initially focusing on manufacturing formulations. Over the years, it expanded its operations by merging with Lyphin Chemicals Pvt Ltd and diversifying into various product lines, including ayurvedic and animal health care products. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 42 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 2 Cr (Quarterly Results - Jun 2026)<BR>- Market cap: INR 269 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.51<BR>- Return on Equity: -10.87%<BR>- Price to Book: 2.91<BR><BR>Contact Details:<BR>Address: 4801/B & 4802/A, GIDC Industrial Estate Ankleshwar Gujarat : 393002<BR>Tel: 91-02646-221422/220549<BR>Email: companysecretary@lykalabs.com<BR>Website: http://www.lykalabs.com

Who are the peers of the Lyka Labs?

Lyka Labs' peers include Medicamen Biotec, BDH Industries, Zenotech Lab, Astonea Labs, Everest Organics, Aarey Drugs, Nectar Lifesci, Kerala Ayurveda, and Sanjiv.Parant, with varying management risks and growth ratings; Lyka Labs has a 1-year return of -24.29%, better than Kerala Ayurveda's -63.87% but worse than Astonea Labs' 57.61%.

Peers: The peers of Lyka Labs are Medicamen Biotec, BDH Industries, Zenotech Lab., Astonea Labs, Everest Organics, Aarey Drugs, Nectar Lifesci., Kerala Ayurveda, and Sanjiv.Parant.<BR><BR>Quality Snapshot: Excellent management risk is observed at BDH Industries and Sanjiv.Parant., while Average management risk is found at Medicamen Biotec, Zenotech Lab., Astonea Labs, Everest Organics, Lyka Labs, Nectar Lifesci., and the rest. Below Average management risk is noted at Aarey Drugs and Kerala Ayurveda. Growth is rated as Good at Astonea Labs, while Below Average growth is seen at Medicamen Biotec, BDH Industries, Zenotech Lab., Everest Organics, Lyka Labs, Nectar Lifesci., Aarey Drugs, and the rest. Capital Structure is Excellent at BDH Industries and Zenotech Lab., Good at Medicamen Biotec, and Below Average at Astonea Labs, Everest Organics, Aarey Drugs, Lyka Labs, Nectar Lifesci., Kerala Ayurveda, and the rest.<BR><BR>Return Snapshot: Astonea Labs has the highest 1-year return at 57.61%, while Kerala Ayurveda has the lowest at -63.87%. Lyka Labs' 1-year return of -24.29% is better than Kerala Ayurveda's but worse than Astonea Labs'. Additionally, the six-month return is negative for Everest Organics, Kerala Ayurveda, and Lyka Labs.

How big is Lyka Labs?

As of 31st August, Lyka Labs Ltd has a market capitalization of 269.00 Cr and reported Net Sales of 137.73 Cr with a Net Profit loss of 8.90 Cr in the latest four quarters. Shareholder's Funds are 92.39 Cr and Total Assets are valued at 174.54 Cr as of March 2026.

As of 31st August, Lyka Labs Ltd has a market capitalization of 269.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Lyka Labs reported Net Sales of 137.73 Cr. However, the company experienced a Net Profit loss of 8.90 Cr during the same period.<BR><BR>The latest reporting period for the balance sheet is March 2026. Shareholder's Funds stand at 92.39 Cr, while Total Assets are valued at 174.54 Cr.

Should I buy, sell or hold Lyka Labs Ltd?

When is the next results date for Lyka Labs Ltd?

The next results date for Lyka Labs Ltd is 10 August 2026.

The next results date for Lyka Labs Ltd is scheduled for 10 August 2026.

Are Lyka Labs Ltd latest results good or bad?

Lyka Labs Ltd's latest Q4 FY26 results are concerning, showing a net loss of ₹7.61 crores and a 16.15% revenue decline, marking the lowest quarterly revenue in seven quarters. Analysts have downgraded the company's financial outlook to "Negative," indicating significant operational challenges and a bleak future without a turnaround strategy.

Lyka Labs Ltd's latest results for Q4 FY26 are concerning and indicate a significant deterioration in financial performance. The company reported a net loss of ₹7.61 crores, which marks a drastic decline of 529.94% year-on-year. Revenue also fell to ₹28.03 crores, down 16.15% compared to the same quarter last year and representing the lowest quarterly revenue in the past seven quarters.<BR><BR>The operating margin has turned deeply negative at -23.05%, the worst level recorded, and the profit after tax (PAT) margin is at -28.79%, highlighting severe operational inefficiencies. The company's financial trend has been downgraded to "Negative" by analysts, reflecting growing concerns about its operational viability.<BR><BR>Additionally, the stock has underperformed significantly, declining 47.08% over the past year, which is starkly worse than both the Sensex and the pharmaceuticals sector. Overall, these results suggest that Lyka Labs is facing a critical operational crisis, and the outlook appears bleak without a clear turnaround strategy.

Is Lyka Labs overvalued or undervalued?

As of November 13, 2025, Lyka Labs is considered overvalued with a high PE ratio of 156.53 and a significant decline in performance, contrasting with its peers, which have more attractive valuations and growth expectations.

As of 13 November 2025, Lyka Labs has moved from an attractive to a fair valuation grade, indicating a shift in its perceived investment quality. The company is currently considered overvalued based on its high PE ratio of 156.53, an EV to EBIT of 119.79, and a Price to Book Value of 3.16. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Lyka Labs' PE ratio significantly exceeds that of Cipla, which stands at 22.65, and Dr. Reddy's Labs at 17.86, both of which are classified as attractive. Additionally, while Lyka Labs has a PEG ratio of 0.00, indicating no growth expectations, its peers like Sun Pharma and Divi's Lab are categorized as expensive with PEG ratios of 11.96 and 1.99, respectively. The recent performance of Lyka Labs shows a substantial decline, with a year-to-date return of -43.61%, contrasting sharply with the Sensex's positive return of 8.11% during the same period, further reinforcing the overvaluation narrative.

How has been the historical performance of Lyka Labs?

Lyka Labs has shown fluctuating historical performance, with net sales increasing from 93.07 Cr in Mar'23 to 138.50 Cr in Mar'25, while total operating income peaked at 194.08 Cr in Mar'22 before declining. Despite rising costs and low cash flow, the company improved profitability, achieving a profit after tax of 7.93 Cr in Mar'25, recovering from previous losses.

Answer:<BR>The historical performance of Lyka Labs shows a fluctuating trajectory over the years, with notable improvements in recent periods.<BR><BR>Breakdown:<BR>Lyka Labs' net sales increased from 93.07 Cr in Mar'23 to 138.50 Cr in Mar'25, reflecting a positive growth trend. However, the total operating income peaked at 194.08 Cr in Mar'22 before declining to 138.50 Cr in Mar'25. The total expenditure, excluding depreciation, rose from 76.23 Cr in Mar'23 to 120.56 Cr in Mar'25, indicating rising costs. Operating profit (PBDIT) showed volatility, with a high of 103.24 Cr in Mar'22, dropping to 20.17 Cr in Mar'25. Profit before tax improved to 11.12 Cr in Mar'25 from a loss of 13.23 Cr in Mar'23, while profit after tax also turned positive at 7.93 Cr in Mar'25, recovering from losses in previous years. The company's total assets increased to 176.21 Cr in Mar'25, up from 151.52 Cr in Mar'23, and total liabilities also rose to 176.21 Cr in Mar'25. Cash flow from operating activities remained low at 1.00 Cr in Mar'25, with a net cash outflow of 4.00 Cr. Overall, while Lyka Labs has shown signs of recovery in profitability and sales, it continues to face challenges with rising costs and cash flow management.

What is the technical trend for Lyka Labs?

As of June 2, 2025, Lyka Labs shows a mildly bearish trend, supported by daily moving averages and a bearish monthly MACD, despite mixed signals from the weekly MACD and Bollinger Bands.

As of 2 June 2025, the technical trend for Lyka Labs has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are also mildly bearish, reinforcing the bearish sentiment. Bollinger Bands on the monthly chart show a bearish trend, while both the KST and Dow Theory indicate no clear trend on a monthly basis. Overall, the current stance is mildly bearish, with the daily moving averages and monthly MACD being key indicators driving this outlook.

Who are the top shareholders of the Lyka Labs?

The top shareholders of Lyka Labs primarily include promoters, with Ipca Laboratories Limited as the largest shareholder at 40.98%. Other notable shareholders are Thermo Capital Private Limited (1.55%) and individual investors (31.18%), along with minimal stakes from mutual funds and foreign institutional investors.

The top shareholders of Lyka Labs include several key players. The majority of the shares are held by promoters, with Ipca Laboratories Limited being the largest individual shareholder, holding 40.98%. Other notable shareholders include Thermo Capital Private Limited, which holds 1.55%, and individual investors collectively owning 31.18%. Additionally, there are four mutual fund schemes with a very small stake of 0.01% and five foreign institutional investors (FIIs) holding 0.23%. Overall, the promoter group plays a significant role in the ownership structure of Lyka Labs.

Has Lyka Labs declared dividend?

No Dividend History Available